7YV1

Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor LUNA18 and KA30L Fab

Summary for 7YV1

• Entry DOI: 10.2210/pdb7yv1/pdb
• Descriptor: Isoform 2B of GTPase KRas, KA30L Fab H-chain, KA30L Fab L-chain, ... (7 entities in total)
• Functional Keywords: k-ras, cyclic peptide, oncology, signaling protein-inhibitor complex, signaling protein
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 4
• Total formula weight: 69432.56

Authors

Irie, M.,Fukami, T.A.,Matsuo, A.,Saka, K.,Nishimura, M.,Saito, H.,Torizawa, T.,Tanada, M.,Ohta, A. (deposition date: 2022-08-18, release date: 2023-07-26, Last modification date: 2023-11-22)

Primary citation

Ohta, A.,Tanada, M.,Shinohara, S.,Morita, Y.,Nakano, K.,Yamagishi, Y.,Takano, R.,Kariyuki, S.,Iida, T.,Matsuo, A.,Ozeki, K.,Emura, T.,Sakurai, Y.,Takano, K.,Higashida, A.,Kojima, M.,Muraoka, T.,Takeyama, R.,Kato, T.,Kimura, K.,Ogawa, K.,Ohara, K.,Tanaka, S.,Kikuchi, Y.,Hisada, N.,Hayashi, R.,Nishimura, Y.,Nomura, K.,Tachibana, T.,Irie, M.,Kawada, H.,Torizawa, T.,Murao, N.,Kotake, T.,Tanaka, M.,Ishikawa, S.,Miyake, T.,Tamiya, M.,Arai, M.,Chiyoda, A.,Akai, S.,Sase, H.,Kuramoto, S.,Ito, T.,Shiraishi, T.,Kojima, T.,Iikura, H.
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets.
J.Am.Chem.Soc., 145:24035-24051, 2023

PubMed Abstract: Establishing a technological platform for creating clinical compounds inhibiting intracellular protein-protein interactions (PPIs) can open the door to many valuable drugs. Although small molecules and antibodies are mainstream modalities, they are not suitable for a target protein that lacks a deep cavity for a small molecule to bind or a protein found in intracellular space out of an antibody's reach. One possible approach to access these targets is to utilize so-called middle-size cyclic peptides (defined here as those with a molecular weight of 1000-2000 g/mol). In this study, we validated a new methodology to create oral drugs beyond the rule of 5 for intracellular tough targets by elucidating structural features and physicochemical properties for drug-like cyclic peptides and developing library technologies to afford highly -alkylated cyclic peptide hits. We discovered a KRAS inhibitory clinical compound (LUNA18) as the first example of our platform technology.

PubMed: 37874670
DOI: 10.1021/jacs.3c07145

Experimental method

X-RAY DIFFRACTION (1.454 Å)